Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model

Journal of Pharmacological and Toxicological Methods

Volumn 57, Issue 1, 2008, Pages 9-22

  Steidl Nichols, Jill V ^a   Hanton, Gilles ^a   Leaney, Joanne ^b   Liu, Ruei Che ^a   Leishman, Derek ^c   McHarg, Aileen ^a   Wallis, Rob ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

hERG; Methods; Proarrhythmia; QT prolongation; Safety margin; SCREENIT rabbit isolated heart model; Torsades de Pointes; TRIad

Indexed keywords

ASTEMIZOLE; BEPRIDIL; CISAPRIDE; DOFETILIDE; GLUCOSE; HALOPERIDOL; MOXIFLOXACIN; RISPERIDONE; TERFENADINE; VERAPAMIL;

ACTION POTENTIAL; ACTION POTENTIAL DURATION; ACTION POTENTIAL REPOLARIZATION; ACTION POTENTIAL TRIANGULATION; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTROPHYSIOLOGY; EXPERIMENTAL MODEL; EXTRASYSTOLE; FEMALE; HEART; HEART PROARRHYTHMIA; METHODOLOGY; NONHUMAN; PARAMETER; PERFUSION TIME; PREDICTION; QT PROLONGATION; QUALITATIVE ANALYSIS; RABBIT; REVERSE USE DEPENDENCE OF PROLONGATION; RISK ASSESSMENT; SAFETY; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART CONDUCTION SYSTEM; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 36249026535     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2007.06.003     Document Type: Article

References (35)

1. Akita M., Shibazaki Y., Izumi M., Hiratsuka K., Sakai T., Kurosawa T., et al. Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. Journal of Toxicological Sciences 29 (2004) 63-71
2. Alexandrou A.J., Duncan R.S., Sullivan A., Hancox J.C., Leishman D.J., Witchel H.J., et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. British Journal of Pharmacology 147 (2006) 905-916
3. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem?. Journal of Electrocardiology 37 (2004) 15-24
4. Antzelevitch C., and Shimizu W. Cellular mechanisms underlying the long QT syndrome. Current Opinion in Cardiology 17 (2002) 43-61
5. Antzelevitch C., Sicouri S., Litovsky S.H., Lukas A., Krishnan S.C., Di Diego J.M., et al. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circulation Research 69 (1991) 1427-1449
6. Atiga W.L., Calkins H., Lawrence J.H., Tomaselli G.F., Smith J.M., and Berger R.D. Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. Journal of Cardiovascular Electrophysiology 9 (1998) 899-908
7. Aubert M., Osterwalder R., Wagner B., Parrilla I., Cavero I., Doessegger L., et al. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug torsades de pointes in humans. Drug Safety 29 (2006) 237-254
8. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends in Pharmacological Sciences 24 (2003) 619-625
9. Champeroux P., Viaud K., El Amrani A.I., Fowler J.S., Martel E., Le Guennec J.Y., et al. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. British Journal of Pharmacology 144 (2005) 376-385
10. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80 (1995) 795-803
11. De Clerk F., Van de Water A., D'Aubioul J., Lu H.R., Van Rossem K., Hermans A., et al. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: Application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundamental and Clinical Pharmacology 16 (2002) 125-140
12. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., and Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce Torsades de Pointes: An overview. Drug Safety 25 (2002) 263-286
13. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., and Wrighton S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. Journal of Pharmacology and Experimental Therapeutics 301 (2002) 427-434
14. Fossa A.A., Wisialowski T., Wolfgang E., Wang E., Avery M., Raunig D.L., et al. Differential effect of hERG blocking agents on cardiac electrical alternans in the guinea pig. European Journal of Pharmacology 486 (2004) 209-221
15. Galeano E.J., Ohnishi Y., Yoshida A., and Yokoyama M. Usefulness of beat-to-beat QT dispersion fluctuation for identifying patients with coronary heart disease at risk for ventricular arrhythmias. American Journal of Cardiology 88 (2001) 1235-1239
16. Galeano E.J., Yoshida A., Ohnishi Y., Okajima K., Ishida A., Kitamura H., et al. Comparative usefulness of beat-to-beat QT dispersion and QT interval fluctuations for identifying patients with organic heart disease at risk for ventricular arrhythmias. Circulation Journal 67 (2003) 125-128
17. Guanzon A.V., and Crouch M.A. Phase IV trial evaluating the effectiveness and safety of dofetilide. Annals of Pharmacotherapy 38 (2004) 1142-1147
18. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. European Heart Journal 21 (2000) 1216-1231
19. Hondeghem L.M., Carlsson L., and Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103 (2001) 2004-2013
20. Hondeghem L.M., and Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability. Journal of Cardiovascular Pharmacology 41 (2003) 14-24
21. Hondeghem L.M., Lu H.R., van Rossem K., and De Clerck F. Detection of proarrhythmia in the female rabbit heart: Blinded validation. Journal of Cardiovascular Electrophysiology 14 (2003) 287-294
22. Lawrence C.L., Bridgland-Taylor M.H., Pollard C.E., Hammond T.G., and Valentin J.P. A rabbit Langendorff heart proarrhythmia model: Predictive value for clinical identification of Torsades de Pointes. British Journal of Pharmacology 149 (2006) 845-860
23. Milberg P., Ramtin S., Monnig G., Osada N., Wasmer K., Breithardt G., et al. Comparison of the in vitro electrophysiology and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. Journal of Cardiovascular Pharmacology 44 (2004) 278-286
24. Minematsu T., Ohtani H., Yamada Y., Sawada Y., Sato H., and Iga T. Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: Pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. Journal of Pharmacokinetics and Pharmacodynamics 28 (2001) 533-554
25. Physicians' Desk Reference. 57th ed (2003), Thomson PDR, Montvale, NJ
26. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., and Palethorpe. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsades de Pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
27. Sanguinetti M.C., Jiang C., Curran M.E., and Keating M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81 (1995) 299-307
28. Schneider J., Hauser R., Andreas J.O., Linz K., and Jahnel U. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. European Journal of Pharmacology 512 (2005) 53-60
29. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2 (2005) 758-772
30. Snyders D.J., and Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Molecular Pharmacology 49 (1996) 949-955
31. Titier K., Canal M., Deridet E., Abouelfath A., Gromb S., Molimard M., et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: Comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicology and Applied Pharmacology 199 (2004) 52-60
32. Valentin J.P., Hoffmann P., De Clerck F., Hammond T.G., and Hondeghem L. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. Journal of Pharmacological and Toxicological Methods 49 (2004) 171-181
33. Vos M.A., Verduyn S.C., Gorgels A.P.M., Lipcsei G.C., and Wellens H.J.J. Reproducible induction of early afterdepolarizations and Torsades de Pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation 91 (1995) 864-872
34. Weissenburger J., Davy J.M., Chezalviel F., Lainee P., Guhennec C., Penin E., et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. Journal of Pharmacology and Experimental Therapeutics 259 (1991) 871-883
35. Zhou Z., Vorperian V.R., Gong Q., Zhang S., and January C.T. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Journal of Cardiovascular Electrophysiology 10 (1999) 836-843